Studies indicate that GEF offers decent efficacy in Asian patients with EGFR mutation-positive cancer; hence, the mutation status of EGFR must be predetermined before treatment with GEF is commenced, particularly in a first-line clinical setting [162]. This evidence concerns the gene EGFR and cancer.